drugset / Trial / NCT02164812

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

NCT02164812

Phase 1 Completed 58 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-label

Summary

The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 \*1/\*6 and \*6/\*6 healthy subjects.

Timeline

Start
2014-07
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 600 mg
Background Moxifloxacin Small molecule

Indications